Evidence map›Paper›PMID 41142998›Full record

ArticleiScience2025

Evaluation of urinary cfDNA workflows for the molecular profiling of malignant disease.

Anna Eberhard, Tina Moser, Leandra Ziegler, Georgios Vlachos, Martina Loibner, Thomas Bauernhofer, Marija Balic, Armin Gerger, Nadia Dandachi, Christine Beichler and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Anna EberhardInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Styria, Austria.
Tina MoserInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Styria, Austria.
Leandra ZieglerInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Styria, Austria.
Georgios VlachosInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Styria, Austria.
Martina LoibnerDepartment of Internal Medicine Graz, Division of Oncology, Medical University of Graz, Graz, Styria, Austria.
Thomas BauernhoferDepartment of Internal Medicine Graz, Division of Oncology, Medical University of Graz, Graz, Styria, Austria.
Marija BalicDepartment of Internal Medicine Graz, Division of Oncology, Medical University of Graz, Graz, Styria, Austria.
Armin GergerDepartment of Internal Medicine Graz, Division of Oncology, Medical University of Graz, Graz, Styria, Austria.
Nadia DandachiDepartment of Internal Medicine Graz, Division of Oncology, Medical University of Graz, Graz, Styria, Austria.
Christine BeichlerInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Styria, Austria.
Lisa GlawitschInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Styria, Austria.
Matthias MoserInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Styria, Austria.
Ricarda GrafInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Styria, Austria.
Peter M AbujaInstitute of Pathology, Diagnostic & Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Styria, Austria.
Markus SchmitzPreAnalytiX GmbH, Hombrechtikon, Switzerland.
Tomasz KrenzPreAnalytiX GmbH, Hombrechtikon, Switzerland.
Thorsten VossPreAnalytiX GmbH, Hombrechtikon, Switzerland.
Daniela MancarellaPreAnalytiX GmbH, Hombrechtikon, Switzerland.
Ellen HeitzerInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Styria, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary cell-free DNA (ucfDNA) is a promising liquid biopsy analyte obtained by a non-invasive sampling method, particularly valuable in urological cancers due to the proximity of biofluids to the tumor site. However, extremely high fragmentation and low abundance of ucfDNA pose significant analytical challenges. Improper handling and storage can severely affect ucfDNA quality, necessitating optimized pre-analytical workflows for clinical applications. We evaluated multiple pre-analytical workflows, including urine stabilization approaches against unstabilized urine samples. Our results demonstrated that without stabilization, ucfDNA degraded rapidly and minimal quantities remaining after 72 h. In contrast, urine stabilization preserved ucfDNA integrity, enabling successful downstream analyses, including digital PCR and next-generation sequencing, for mutation detection in cancer-related genes and genome wide copy number profiling. These findings underscore the critical role of stabilization for a reliable ucfDNA analysis and highlight its potential in molecular diagnostics as a complementary tool to plasma-based liquid biopsies.

Indexed as

Diagnostic procedureDiagnostic technique in health technologyFluid

Identifiers

PMID41142998
PMCPMC12547846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.